Hindustan Times ST (Jaipur)

Pay ₹74.5L to faulty hip implant patient: Government to J&J

ORDER In first such move, firm will have to give amount within 30 days

- Rhythma Kaul letters@hindustant­imes.com

NEW DELHI: Three months after the health ministry approved compensati­on for patients who received Johnson & Johnson (J&J)’S faulty hip implants before August 2010, the government has directed the company to pay ₹74.5 lakh to a patient in the first such order.

On November 29, 2018, a central expert committee under the ministry approved a compensati­on amount between ₹30 lakh and ₹1.23 crore, based on a specific formula it created to determine compensati­on amount for the affected patients.

The amount was to be calculated on case-to-case basis depending on the age and the level of disability of a person, with younger people having higher disability getting the maximum compensati­on.all states were asked to form a statelevel committee, to track and verify eligible patients, and to come up with an amount on the basis of the central committee’s formula.

On Friday, the Central Drugs Standard Control Organisati­on (CDSCO) directed J&J to pay the compensati­on amount to a patient from Maharashtr­a within 30 days from the date receipt of the order. Also, a copy of acknowledg­ment from the patient about the compensati­on paid must be s ubmitted t o CDSCO within the same period.

The applicatio­n of the Maharashtr­a patient was examined by the state-level committee that had forwarded their recommenda­tion to the central committee.

“The central committee, after examining the documents, is of the opinion that the patient implanted with faulty Articular Surface Replacemen­t (ASR) hip implant on both hips and subsequent revision of left hip, is entitled for the financial compensati­on of ₹74,57,180 as per the formula,” read the CDSCO notice.

This is the first case where J&J has been directed to pay compensati­on to a victim of the faulty hip implant surgery.

While the company refused to comment on the notice, saying it was subjudice, the central drug controller appeared hopeful of compliance. “We will have to think positive,” said Dr S Eswara Reddy, the Drug Controller General of India.around 200 applicatio­ns are under considerat­ion for awarding the compensati­on.

The faulty ASR hip implants manufactur­ed by Depuy Internatio­nal Limited, a subsidiary of J&J Pvt Ltd, were recalled in 2010 globally with complaints of more than usual revision surgeries because of complicati­ons such as metal leaching and infections, among other complicati­ons.following complaints from patients, the health ministry set up an 11-member committee on February 7, 2017, to investigat­e patient complaints of adverse events against the implant. The report was submitted in February 2018 and had recommende­d a base amount of ₹20 lakh.

Based on the recommenda­tions, the government constitute­d an expert committee to determine the quantum of compensati­on.

 ??  ??

Newspapers in English

Newspapers from India